0514 GMT - Top Glove's earnings are on the cusp of a progressive recovery this year, UOB Kay Hian analyst Jack Goh says in a note. The glove maker is likely to benefit from U.S. tariff hikes, including the additional 10% levy on Chinese goods, he writes. That could entice U.S. distributors to stop importing medical gloves from Chinese producers and instead buy from Malaysian manufacturers such as Top Glove, he says. The current risk-reward tradeoff appears fair but still provides palatable upside based on 2026 valuations, he adds. UOB KH maintains the stock's hold rating and target price of MYR1.31. Shares last closed at MYR1.22. (amanda.lee@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 00:14 ET (05:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.